top of page


【The 7th Liquid Biopsy Seminar in Japan】

CytoAurora Biotechnologies fully discussed our precision technology and detection applications at the Liquid Biopsy Research Conference in Tokyo on 1/28, and once again became famous internationally and amazed everyone, breaking through the limitations of the public on the existing CTC technology.

*Liquid Biopsy Research Association: Sponsored by the "Urology Department of Keio University School of Medicine" and composed of many well-known hospitals, medical centers and tumor gene research teams in Japan.

【CytoAurora was invited by J.P. Morgan to give a speech at the RESI conference and achieved great results】

The 41st Annual Healthcare Conference will take place on January 9-12, 2023 in San Francisco, CA.
This premier conference is the largest and most informative healthcare investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health (4 Ds). RRESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare.

Invited by J.P. Morgan this time, CytoAurora Biotechnologies shared our single-cell technology combined with semiconductor technology at the RESI conference, and demonstrated the latest technology trends and future developments. It was favored by international professionals and won the second place.

【CES2023 ended successfully in Las Vegas】

This year, the first step of CytoAurora Biotechnologies is to show its talents at the CES exhibition. We aim at the field of precision medicine, and bring the latest single-cell technology combined with semiconductor technology to advance to the most index consumer electronics exhibition in the global science and technology industry, and We gain international attention at the exhibition.

Approaching the 2023 CES
with CytoAurora Biotechnologies

CytoAurora Biotechnologies has been shortlisted for two consecutive years and won the 2023 CES Award. We are eagerly looking forward to participating in the most eye-catching event in the world. CytoAurora Biotechnologies will participate in the CES exhibition in Las Vegas from January 5 to January 9, 2023 and demonstrated innovative single-cell technology and development trends.


Adhering to the spirit of self-owned technology, independent innovation, and sustainable invention, CytoAurora Biotechnologies is marching towards the international market!


Based in Taiwan, look at the world!

Annual Taiwan Medical Technology Exhibition
-From 2022/12/1 to 2022/12/4

Taiwan Medical Technology Exhibition is the world's first professional-scale exhibition that "spans medical care, electronic information and communication, technology, biotechnology and pharmaceuticals, and medical materials, and connects the complete ecological chain of the big health industry." It gathers Taiwan's top medical systems, electronic technologies Dachang, index biotechnology and pharmaceutical company!

After participating in the annual event of the medical biotechnology industry last year, our company has continued to improve and expand this year. We not only promised to continue to provide diversified testing services, but also exhibited the latest generation of equipment "Cell Reveal" for the first time. A new range of single-cell technologies was presented on the show floor.

We were honored at the 2023 CES Innovation Awards

CytoAurora won the "Digital Health" project innovation award with the latest generation of equipment - "Cell Reveal" in the international index award "CES 2023 Innovation Awards". In addition, we are the only one in the industry in Taiwan to win this award.
Our general manager, Dr. Huang, said that this award is one of the most eye-catching awards in the world for technology, revealing the latest technology development trends and innovative applications in the technology market.
Under the competition of many products all over the world, our company won the award with this MIT technology, fully demonstrating the outstanding innovation and R&D strength of Taiwan.


Congratulations! ! ! CytoAurora Biotechnology
CR3-Successfully applied for TFDA medical device license

Since the device Cell Reveal Series 3 developed by us has obtained the Taiwan TFDA medical device license. In November 2021, Cell Reveal Series 3 successfully passed the "Medical Device Filing Certificate" certification in mainland China [Certificate No. 20210323], and we will continue to work hard to improve better precision medical testing in the field of testing services quality.

↑​Click to see more ↑

Well-known magazine ”Life Science Review”: Taiwanese PhD entrepreneur, breaking through the technical bottleneck of CTC

The international magazine《Life Science Review》published in July 2021: Introduce the latest circulating tumor cell (CTC) technology, which is the core technology of CytoAurora, can be applied to early cancer treatment, monitoring, and therapeutic effects. Its various roles in auxiliary diagnosis provide reference basis for companion diagnosis.

Research Papers

Published research papers

圖片 25.png


CytoAurora participate in academic activities

圖片 11.png
bottom of page